Previous 10 | Next 10 |
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Fluphenazine Hydrochloride Tablets, USP, a therapeutic equivalent generic ve...
Dr. Reddy’s Laboratories (RDY) announces the launch of Capecitabine Tablets, USP a therapeutic equivalent generic version of Roche's Xeloda (capecitabine) Tablets. According to IQVIA Health, the Xeloda brand and generic had U.S. sales of ~$90M for year ended October 2020. Dr. Reddy...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Capecitabine Tablets, USP a therapeutic equivalent generic version of Xeloda...
Dr. Reddy’s Laboratories (RDY) announces the launch of Vigabatrin Tablets USP, 500 mg, a therapeutic equivalent generic version of Lundbeck's Sabril (vigabatrin) Tablets. According to IMS Health, the Sabril brand and generic had U.S. sales of ~$141M for the year ended December 2020. Dr...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Vigabatrin Tablets USP, 500 mg, a therapeutic equivalent generic version of ...
Dr. Reddy's Laboratories Limited (RDY) Q3 2021 Earnings Conference Call January 29, 2021 07:00 AM ET Company Participants Amit Agarwal - Head-Investor Relations Erez Israeli - Chief Executive Officer Parag Agarwal - Chief Financial Officer Conference Call Participants Shanti Patel - Shanti Pa...
The following slide deck was published by Dr. Reddy's Laboratories Limited in conjunction with their 2021 Q3 earnings call. For further details see: Dr. Reddy's Laboratories Limited 2021 Q3 - Results - Earnings Call Presentation
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and the nine months ended December 31, 2020. The information mentioned in this release is on the basis of consolidated fina...
Dr. Reddy’s Laboratories (RDY) and Global Response Aid FZCO ((GRA)) have terminated Avigan trial study conducted in Kuwait focused on moderate to severe COVID-19 patients in a hospital setting. The Phase-III study, being conducted in an outpatient setting on patients with mild to moder...
Study for hospitalized moderate to severe cases in Kuwait terminated, while study for out-patient mild to moderate cases continues in North America Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries to...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...